reconstitution is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-31. Numbers and descriptions here follow the published literature rather than marketing material.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Cyclic heptapeptide, C-terminally amidated |
| Approximate molecular mass | 1024 Da | Monoisotopic mass of the free peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Soluble in water and polar solvents | Also dissolves in neutral aqueous buffer |
| Common synonyms | Melanotan II, MT-II, MT-2 | Described as a melanocortin agonist in early literature |
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Canada was one of the first countries to condemn Iraq's invasion of Kuwait, and it quickly agreed to join the US-led coalition. In August 1990, Prime Minister Brian Mulroney committed the Canadian Forces to deploy a Naval Task Group. The destroyers HMCS Terra Nova and HMCS Athabaskan joined the maritime interdiction force supported by the supply ship HMCS Protecteur in Operation Friction. The Canadian Task Group led the coalition's maritime logistics forces in the Persian Gulf. A fourth ship, HMCS Huron, arrived in-theater after hostilities had ceased and was the first allied ship to visit Kuwait. Following the UN-authorized use of force against Iraq, the Canadian Forces deployed a CF-18 Hornet and CH-124 Sea King squadron with support personnel, as well as a field hospital to deal with casualties from the ground war. When the air war began, the CF-18s were integrated into the coalition force and provided air cover and attacked ground targets. This was the first time since the Korean War that the Canadian Armed Forces had participated in an offensive. The only CF-18 Hornet to record an official victory during the conflict was an aircraft involved in the beginning of the Battle of Bubiyan against the Iraqi Navy.
== Enzyme structure == Enteropeptidase is a type II transmembrane serine protease (TTSP) localized to the brush border of the duodenal and jejunal mucosa and synthesized as a zymogen, proenteropeptidase, which requires activation by duodenase or trypsin. TTSPs are synthesized as single chain zymogens with N-terminal propeptide sequences of different lengths. These enzymes are activated by cleavage at the carboxyl side of lysine or arginine residues present in a highly conserved activation motif. Once activated, TTSPs are predicted to remain membrane-bound through a conserved disulfide bond linking the pro- and catalytic domains. In the case of cattle enteropeptidase the primary translation product comprises 1035 residues with an expected mass of 114.9 kDa. The detected apparent mass of about 160 kDa is consistent with the specified carbohydrate content of 30 - 40%, with equal amounts of neutral and amino sugars. The activation cleavage site after Lys800 splits the heavy and light chains of mature cattle enteropeptidase. There are 17 potential N-linked glycosylation sites in the heavy chain and three in the light chain; most of these are conserved in other species. The heavy chain has a hydrophobic section near the N-terminus that supports the transmembrane anchor. The heavy chain influences the specificity of enteropeptidase. Native enteropeptidase is resistant to soybean trypsin inhibitor. However, the isolated light chain is subtle whether prepared by limited reduction of the natural protein or by mutagenesis and expression in COS cells.
Acacia acinacea Acacia baileyana Acacia decurrens Acacia dealbata Acacia mearnsii Acacia drummondii Acacia elata Acacia falcata Acacia leprosa Acacia linearis Acacia melanoxylon Acacia retinodes Acacia saligna Acacia stricta Acacia verticillata Acacia visco Acacia vestita
Produced by Hilary Lawson, made by TVF Media 15 December Rheumatoid Arthritis, British scientists have discovered that sufferers lack a sugar in part of their immune system, namely the glycosylation of glycans on Immunoglobulin G (IgC); David Isenberg at Middlesex Hospital; the Pima tribe in Arizona, studied by British doctor Peter Bennett; the Hu Hu Kam Memorial Hospital in Sacaton, Arizona; Raymond Dwek researched glycobiology, how sugar molecules attached to the surface of cells; Tom Rademacher found that arthritis disappeared during pregnancy; Graham Rook, who researched microbiology at UCL, developed a biochemical test at Middlesex Hospital; people developed arthritis, in groups, across Lyme, Connecticut; Allen Steere of New England Medical Centre, who named Lyme disease.
Quantitative proteomics is an analytical chemistry technique for determining the amount of various proteins, including cofactors, in a sample. The methods for protein identification and separation are identical to those used in general qualitative proteomics, but include quantification as an additional dimension. Rather than just providing lists of proteins identified in a certain sample, quantitative proteomics yields information about the physiological differences between two biological samples. For example, this approach can be used to compare samples from healthy and diseased patients. Quantitative proteomics is mainly performed by two-dimensional gel electrophoresis (2-DE), preparative native PAGE, or mass spectrometry (MS). However, a recent developed method of quantitative dot blot (QDB) analysis is able to measure both the absolute and relative quantity of individual proteins in the sample in high throughput format, thus, open a new direction for proteomic research. In contrast to 2-DE, which requires MS for the downstream protein identification, MS technology can identify and quantify the structural changes and physiological functions.
Sources: en.wikipedia.org
=== Absorption === The oral bioavailability of CPA is 68 to 100%. The absorption of oral CPA is slow but complete, and the medication is not subject to a significant first-pass effect. The mean absorption half-life of oral CPA is about 1.5 hours. Steady-state levels of CPA occur with oral CPA after about 8 days of continuous administration, with a 2- to 3-fold gradual accumulation in CPA levels. Oral CPA is taken daily and intramuscular CPA is administered weekly or biweekly. Following a single low oral dose of 2 mg CPA in combination with 35 or 50 μg ethinylestradiol in premenopausal women, mean peak levels of CPA of 7.2 to 15.2 ng/mL (17–36.5 nmol/L) have been recorded after 1.6 to 3.7 hours. In healthy men, a single high oral dose of 100 mg CPA produced maximal CPA levels of 254 ng/mL (609 nmol/L) after 2.6 hours. In aged men with prostate cancer, continuous oral CPA therapy resulted in CPA levels of 132 ± 18 ng/mL at 25 mg/day, 246 ± 13 ng/mL at 50 mg/day, and 348 ± 23 ng/mL at 100 mg/day. Similarly, in healthy young women, a single high oral dose of 100 mg CPA resulted in peak CPA levels of 255 ng/mL (612 nmol/L) within 2 to 3 hours. During continuous treatment with high oral doses of CPA in women with hirsutism, levels of CPA were 199 to 228 ng/mL (477–547 nmol/L) with 50 mg/day CPA and were 436 to 520 ng/mL (1050–1250 nmol/L) with 100 mg/day CPA. After a single intramuscular injection of 300 mg CPA in healthy young women, maximal levels of CPA of 191 ng/mL (458 nmol/L) and of 15β-OH-CPA of 164 ng/mL occurred after 2 to 4 days.
== History == Prior to the UGR's implementation, the U.S. military had several different types of rations used to feed service members in the rear or out of combat. Among them were the A-ration, consisting of fresh, refrigerated, or frozen food prepared in a kitchen and served in a mess, dining facility, or elsewhere; the B-ration, consisting of packaged, preserved foods prepared in a field kitchen; and the T-ration, a semi-perishable meal packaged, heated, and served in a tray pack similar to frozen meals; among others. This created issues for military cooks, who "had to order an average of 34 separate items for each meal, and could only hope that they arrived when needed", forcing them to manage logistics and administrative functions instead of solely food preparation. Around 1995, the U.S. military launched a modernization program to resolve this issue while also increasing the quality and decreasing the cost of existing rations. Research was headed by the U.S. Army Natick Soldier Research, Development and Engineering Center and the U.S. Army Quartermaster Center and School. In 1999, the UGR was created to simplify logistics and ensure all necessary ingredients were provided, combining elements and offerings of the A-ration, B-ration, T-ration, and commercial items. The UGR was initially trialed with the Army, with their first shipments received around 2000; the Air Force, Marine Corps, and Navy also began receiving UGRs at unspecified dates. The UGR-E was introduced in 2006. The UGR-B was phased out and replaced by the mostly similar UGR-M at an unspecified date.
demonstrated DE sorting and isolation on-chip followed by FACS that allows for high sorting throughput of encapsulated mammalian cells, from which genetic material can later be extracted. While fluorogenic labeling is a powerful tool for tracking and sorting, it is not always compatible with droplet-based microfluidic systems and experimental design. New label-free and non-fluorescence-based detection techniques have recently been reported. In 2016, Gielen et al. published an absorbance-activated droplet sorting (AADS) microfluidic device and demonstrated its functionality by directing the evolution of a phenylalanine dehydrogenase. In 2016, Sun et al. demonstrated the use of SE droplets and high-throughput MS to screen enzyme activators and inhibitors by screening a transaminase library. In 2019, Pan et al. showed sorting of droplets by interfacial tensions, which are affected by droplet content. In 2020, Haidas et al. presented a microfluidic approach that uses both matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) and fluorescence microscopy, which the authors used to measure the concentration and activity of phytase, respectively, in yeast cells. In 2020, Holland-Moritz et al. published their mass activated droplet sorting (MADS) method, which integrates MS analysis with fluorescence-activated droplet sorting (FADS). Using this method, droplets are split and analyzed separately by both MS and FADS. The power of this method was demonstrated by screening the activity of a transaminase library expressed in vitro.
=== Chemical fingerprinting and breath analysis === The exhaled human breath contains a few thousand volatile organic compounds and is used in breath biopsy and is used in breath biopsy as a biomarker to test for diseases, such as lung cancer. One study has shown that "volatile organic compounds ... are mainly blood borne and therefore enable monitoring of different processes in the body." And it appears that VOC compounds in the body "may be either produced by metabolic processes or inhaled/absorbed from exogenous sources" such as environmental tobacco smoke. Chemical fingerprinting and breath analysis of volatile organic compounds has also been demonstrated with chemical sensor arrays, which utilize pattern recognition for detection of component volatile organics in complex mixtures such as breath gas.
Sources: en.wikipedia.org
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.
Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.
Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.